J&J reports latest data on Balversa-based ‘pretzel’ therapy for bladder cancer
06 May 2024
Drug ApprovalClinical Result
Bladder cancer patients with a common mutation saw promising early results after receiving a Johnson & Johnson targeted therapy that administers the drug sold as Balversa through a slow-releasing pretzel-shaped delivery device.
The treatment, known as TAR-210, delivers the bladder cancer drug slowly over time through a silicone tube called the “pretzel.” Balversa, also known as erdafitinib, is approved as an oral therapy, and hasn’t yet been cleared by the FDA for use in the device. But researchers hope delivering the medication with the device can
spare patients
from some of the drug’s side effects, including anemia, diarrhea, fatigue, mouth sores and hair loss. It’s similar to another experimental J&J bladder cancer treatment, TAR-200, which uses the “pretzel” to deliver chemotherapy.
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Targets
-Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.